News

Hispanics are the largest ethnic minority and one of the most rapidly growing populations in the United States. Prostate cancer represents the highest incident non-cutaneous malignancy in this population.

A secondary analysis of 2 treatment alterations studies demonstrated that 18F-fluciclovine PET/CT scans play a pivotal role in determining if androgen deprivation therapy is appropriate for patients with prostate cancer.

Pembrolizumab has been approved for the adjuvant treatment of adults and pediatric patients with stage IIB or IIC melanoma who have underwent complete resection.

A study presented at the 22nd SUO Annual Meeting did not identify any significant or clinically meaningfully differences in HRQOL in patients with nonmetastatic bladder cancer who receive robotic-assisted vs open radical cystectomy.

Urine cytology specimen NGS was found to be a feasible and valid method of assessing genomic alterations in patients with upper tract urothelial carcinoma.

A presentation at the SUO Annual Meeting underscored best surveillance strategies for patients with low-grade upper tract urothelial carcinoma who have undergone radical nephroureterectomy.

The FDA has approved the combination of rituximab plus chemotherapy to treat children aged between 6 months and 18 years who have advanced-stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL).

The addition of bevacizumab was found to boost responses in patients with epithelial ovarian cancer receiving pembrolizumab.

Sarah Donahue, MPH, AOCNP, shares what drew her to oncology, the daily challenges she faces as a nurse practitioner, and her advice to new oncology nurses on how to overcome those barriers.

The FDA has granted an approval to a subcutaneous daratumumab combination to treat adults with relapsed/refractory multiple myeloma.

An expert from the Institut Curie discusses the risk-benefit ratio associated with NBTXR3 plus radiotherapy for the treatment of patients with soft tissue sarcoma.

Although White women and Black women carry similar rates of pathogenic variants, a study found that White women were almost 5 times more likely to undergo genetic counseling and testing.

In a phase 1 dose-escalation trial, treatment with the investigative agent was well tolerated with no dose-limiting toxicities.

Among patients who had participated in telemedicine, 45% preferred it to in-office visits, highlighting the need to make telemedicine a priority in cancer care.

Patients with relapsed/refractory chronic lymphocytic leukemia experienced positive gene set enrichment after receiving ibrutinib in addition to lisocabtagene maraleucel.

Pooled findings indicate that the quality of life in patients receiving surufantinib for advanced neuroendocrine tumors was comparable to that of placebo.

Patients with neuroendocrine tumors across various origins experienced favorable responses after receiving tidutamab.

A study in France showed that patients with lung cancer, a population initially excluded from COVID-19 vaccination registration trials, were able to safely receive 3 doses.

Physicians urge patients with lymphoid malignancies to continue precautionary COVID-19 measures regardless of vaccination status.

The implementation of the HuCare Quality Improvement Strategy supported superior emotional function for patients newly diagnosed with cancer.

Data presented at the 2021 ASCO Quality Care Symposium demonstrated that in-person interactions had a bigger impact of professional satisfaction than financial stability.

The FDA approval of sirolimus protein-bound particles marks the first approved therapeutic option for patients with advanced PEComa.

Within this intense experience, caregivers can often find themselves physically and emotionally exhausted

A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.

The majority of patients who received telotristat ethyl to treat their carcinoid syndrome reported stable or increased weight at a 6-month follow-up.

Joe Contreras, MD, chair of the Institute of Pain and Palliative Medicine, explains how some common misconceptions may be hindering patients from receiving potentially outcome-improving palliative care.

Patients receiving immune checkpoint inhibitors for renal cell carcinoma or melanoma responded well to the COVID-19 vaccine.

Pembrolizumab represents the first immunotherapy approved to treat patients with renal cell carcinoma in the adjuvant setting.

A total of 7.4% of patients received a secondary or downstream procedure within the 12 months following their lung cancer screening.

New research found that the discontinuation of prophylactic octreotide was not associated with an increased rate or duration of carcinoid crisis in patients with neuroendocrine tumors.